Source: FDA label
| Molecular formula | C225H348N48O68 |
|---|---|
| Molecular weight | 4813 g/mol |
| Registered trials | 301 |
| PubChem CID | 166567236 |
| Drug class | Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC] |
| Brand names | MOUNJARO |
Boxed warning: The FDA label for this compound includes a boxed warning, the FDA's strongest safety warning. See the full prescribing information for details.
Mechanism of Action
12.1 Mechanism of Action Tirzepatide is a GIP receptor and GLP-1 receptor agonist. It contains a C20 fatty diacid that enables albumin binding and prolongs the half-life. Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1. Tirzepatide enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner.
Managing blood sugar with diet and exercise alone is not always enough for people with type 2 diabetes. Tirzepatide is one option doctors may add to a treatment plan, and understanding how it works and what it can cause helps set realistic expectations.
Key takeaways
- Tirzepatide is approved as an adjunct to diet and exercise for glycemic control in type 2 diabetes.
- It works by activating both GIP and GLP-1 receptors, targets involved in insulin and glucagon regulation.
- The FDA-approved brand name is Mounjaro, and the label carries a boxed warning.
- Over 300 registered clinical trials have studied tirzepatide across different populations and uses.
- The most frequently reported issues in safety databases are gastrointestinal, led by nausea and diarrhoea.
What Tirzepatide Is
Tirzepatide is classified as a GIP receptor agonist and a GLP-1 receptor agonist, meaning it activates two hormone receptor systems at once. It includes a fatty acid component that allows it to bind albumin in the blood, which extends how long it remains active in the body. By activating both the GIP and GLP-1 receptors, tirzepatide boosts insulin release after eating and lowers glucagon, and it does so in a way that depends on current blood glucose levels rather than acting constantly.
What Tirzepatide Is Approved For
Tirzepatide, sold under the brand name Mounjaro, is approved as an adjunct to diet and exercise to improve glycemic control. This approval covers adults and pediatric patients ages 10 and older who have type 2 diabetes mellitus. The label for this product carries a boxed warning, which prescribers and patients should be aware of when considering treatment.
What the Evidence Shows
More than 300 clinical trials have registered tirzepatide as a study drug, spanning multiple populations and conditions. Among the sample of studies, a completed Phase 1 trial evaluated tirzepatide in pediatric participants with obesity. A separate Phase 2 trial, currently recruiting, is investigating tirzepatide for partial lipodystrophy, an application outside its approved diabetes indication.
Reported Side Effects
Safety monitoring data for tirzepatide reflect voluntary reports, which capture reported associations rather than confirmed incidence or proven causation. The most commonly reported reactions are gastrointestinal, including nausea (17,092 reports), diarrhoea (10,006), and vomiting (8,267). Medication use error reports are also prominent, with incorrect dose administered (29,672) and extra dose administered (9,608) among the top reported terms. Additional reports include injection site pain, off label use, and instances where the drug was described as ineffective.
FAQ
What is tirzepatide approved to treat?
Tirzepatide is approved as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. It is sold under the brand name Mounjaro. It is not approved for other uses outside this indication.
How does tirzepatide work?
Tirzepatide activates both the GIP and GLP-1 receptors, which are natural targets involved in blood sugar regulation. This dual activation increases insulin secretion after meals and reduces glucagon levels, both in a glucose-dependent manner. A fatty acid component in its structure helps it bind albumin and remain active longer in the body.
Does tirzepatide have a boxed warning?
Yes, the FDA label for tirzepatide includes a boxed warning. Patients should discuss the specifics of this warning with a healthcare provider before starting treatment.
What are the most commonly reported side effects of tirzepatide?
The most frequently reported reactions in safety databases are gastrointestinal, including nausea, diarrhoea, and vomiting. Reports of medication dosing errors, such as incorrect or extra doses administered, are also common. These figures represent report counts submitted to safety databases, not confirmed rates of occurrence or proof that tirzepatide caused the reaction.
Is tirzepatide being studied for other conditions besides type 2 diabetes?
Clinical trial data show tirzepatide has been studied in more than 300 registered trials covering various populations. Examples include a completed pediatric obesity study and an ongoing trial exploring its use for partial lipodystrophy. These investigational uses are separate from its current FDA-approved indication.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: FDA label (Mounjaro) PubChem ClinicalTrials.gov FDA FAERS
Updated 2026-09-19